Smart jab can shrink head and neck cancer tumours within six weeks, trial finds
Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers Doctors have hailed “incredibly encouraging” trial results that show a triple-action smart jab can shrink tumours in head and neck cancer patients within six weeks. Head and neck (…)
Site référencé:
The Guardian
3566.jpg?width=140&quality=85&auto=format&fit=max&s=6b8d8aa1d243e52630ec912240d7c64f, 3566.jpg?width=460&quality=85&auto=format&fit=max&s=2d87713509e54a6825bcd7efa979683a, 3566.jpg?width=700&quality=85&auto=format&fit=max&s=0f55e3e23cd4fdddf1f92afd52d64c83
